Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 75 Records) |
| Query Trace: Breast Neoplasms and MTOR[original query] |
|---|
| PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO open 2021 9 6 (5): 100230. Dumbrava E E, Call S G, Huang H J, Stuckett A L, Madwani K, Adat A, Hong D S, Piha-Paul S A, Subbiah V, Karp D D, Fu S, Naing A, Tsimberidou A M, Moulder S L, Koenig K H, Barcenas C H, Kee B K, Fogelman D R, Kopetz E S, Meric-Bernstam F, Janku |
| Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics. Journal of Cancer 2021 6 12 (14): 4408-4417. Xiao Weikai, Zhang Guochun, Chen Bo, Chen Xiaoqing, Wen Lingzhu, Lai Jianguo, Li Xuerui, Li Min, Liu Hao, Liu Jing, Han-Zhang Han, Lizaso Analyn, Liao Ni |
| Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Apr . Lim Bora, Potter David A, Salkeni Mohamad A, Silverman Paula, Haddad Tufia C, Forget Frederic, Awada Ahmad, Canon Jean-Luc, Danso Michael, Lortholary Alain, Bourgeois Hugues, Tan-Chiu Elizabeth, Vincent Sylvie, Bahamon Brittany, Galinsky Kevin J, Patel Chirag, Neuwirth Rachel, Leonard E Jane, Diamond Jennifer |
| The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study. International journal of molecular sciences 2021 3 22 (4): . Ko?odziej Przemys?aw, Nico? Marcin, Krawczyk Pawe? A, Bogucki Jacek, Karczmarczyk Agnieszka, Zalewski Daniel, Kubrak Tomasz, Ko?odziej El?bieta, Makuch-Kocka Anna, Madej-Czerwonka Barbara, P?achno Bartosz J, Kocki Janusz, Bogucka-Kocka An |
| Molecular Characterization, Via Next-Generation Sequencing, of Refractory or Resistant Invasive Breast Carcinoma. Cureus 2021 12 13 (11): e19528. Pose Lapausa Patricia, Soria Comes Teresa, Calabria Inés, Maestu Maiques Inmacula |
| Meta-analysis of the association between mTORC1-related genes polymorphisms and cancer risk. Pathology, research and practice 2021 11 229 153696. Lu Xiaoling, Liu Meitong, Liao Yuxiao, Huang Chao, Chai Longlong, Jin Yuchen, Xiong Qiantao, Chen Bife |
| Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype. PLoS genetics 2021 Nov 17 (11): e1009876. Madsen Ralitsa R, Erickson Emily C, Rueda Oscar M, Robin Xavier, Caldas Carlos, Toker Alex, Semple Robert K, Vanhaesebroeck Ba |
| Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Scientific reports 2021 1 11 (1): 82. Anand Kartik, Patel Tejal, Niravath Polly, Rodriguez Angel, Darcourt Jorge, Belcheva Anna, Boone Toniva, Ensor Joe, Chang Jen |
| Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas. Oncogenesis 2022 9 11 (1): 53. Karihtala Peeter, Porvari Katja, Roininen Nelli, Voutilainen Sari, Mattson Johanna, Heikkilä Päivi, Haapasaari Kirsi-Maria, Selander Kat |
| Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer. Cancer genomics & proteomics 0 19 (4): 464-476. Stella Stefania, Vitale Silvia Rita, Massimino Michele, Motta Gianmarco, Longhitano Claudio, Lanzafame Katia, Martorana Federica, Fazzari Carmine, Vecchio Giada Maria, Tirrò Elena, Inzerilli Nicola, Carciotto Rosaria, Manzella Livia, Caruso Michele, Vigneri Pao |
| Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. Targeted oncology 2022 6 17 (3): 355-368. Choo Joan R E, Jan Yi-Hua, Ow Samuel G W, Wong Andrea, Lee Matilda Xinwei, Ngoi Natalie, Yadav Kritika, Lim Joline S J, Lim Siew Eng, Chan Ching Wan, Hartman Mikael, Tang Siau Wei, Goh Boon Cher, Tan Hon Lyn, Chong Wan Qin, Yvonne Ang Li En, Chan Gloria H J, Chen Shu-Jen, Tan Kien Thiam, Lee Soo Ch |
| Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer. Breast cancer research and treatment 2022 5 194 (2): 231-241. Oshi Masanori, Gandhi Shipra, Yan Li, Tokumaru Yoshihisa, Wu Rongrong, Yamada Akimitsu, Matsuyama Ryusei, Endo Itaru, Takabe Kazua |
| Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer. Applied biochemistry and biotechnology 2022 5 194 (9): 3961-3973. Wei Benjie, Shan Yanhong, Du Zhaoli, Yin Chunxia, Zhang Qianqian, Lin Haifeng, Zhang Guirong, Song Dong, Zuo Hongb |
| GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications biology 2022 4 5 (1): 373. Bianco Gaia, Coto-Llerena Mairene, Gallon John, Kancherla Venkatesh, Taha-Mehlitz Stephanie, Marinucci Mattia, Konantz Martina, Srivatsa Sumana, Montazeri Hesam, Panebianco Federica, Tirunagaru Vijaya G, De Menna Marta, Paradiso Viola, Ercan Caner, Dahmani Ahmed, Montaudon Elodie, Beerenwinkel Niko, Kruithof-de Julio Marianna, Terracciano Luigi M, Lengerke Claudia, Jeselsohn Rinath M, Doebele Robert C, Bidard François-Clément, Marangoni Elisabetta, Ng Charlotte K Y, Piscuoglio Salvato |
| Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. International journal of cancer 2022 2 150 (12): 2072-2082. Johansson Annelie, Yu Nancy Y, Iftimi Adina, Tobin Nicholas P, van 't Veer Laura, Nordenskjöld Bo, Benz Christopher C, Fornander Tommy, Perez-Tenorio Gizeh, Stål Olle, Esserman Laura J, Yau Christina, Lindström Linda |
| Somatic Mutations Alter Interleukin Signaling Pathways in Grade II Invasive Breast Cancer Patients: An Egyptian Experience. Current issues in molecular biology 2022 12 44 (12): 5890-5901. Nassar Auhood, Zekri Abdel Rahman N, Elberry Mostafa H, Lymona Ahmed M, Lotfy Mai M, Abouelhoda Mohamed, Youssef Amira Salah El-D |
| MACF1 mutations predict poor prognosis: a novel potential therapeutic target for breast cancer. American journal of translational research 2022 12 14 (11): 7670-7688. Tian Ye, Zhu Kongjun, Li Yuefei, Ren Zhen, Wang Ju |
| Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis. Frontiers in oncology 2023 9 13 1192946. Ta-Chung Chao, Yi-Fang Tsai, Chun-Yu Liu, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Jiun-I Lai, Chih-Yi Hsu, Jiun Jen Lynn, Chi-Cheng Huang, Ling-Ming Tse |
| [Characteristics of PIK3CA gene mutations in Her2-low breast cancer]. Arkhiv patologii 2023 8 85 (4): 5-11. I A Pavlenko, P E Povilaitite, N S Makarevich, V Yu Kaciyaev, A V Petr |
| Cuproptosis/ferroptosis-related gene signature is correlated with immune infiltration and predict the prognosis for patients with breast cancer. Frontiers in pharmacology 2023 7 14 1192434. Jixian Li, Wentao Zhang, Xiaoqing Ma, Yanjun Wei, Fengge Zhou, Jianan Li, Chenggui Zhang, Zhe Ya |
| PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study. Journal of clinical pathology 2023 6 . Federica Miglietta, Valentina Carraro, Ottavia Amato, Gaia Griguolo, Michele Bottosso, Giada Munari, Giovanni Zarrilli, Marcello Lo Mele, Caterina Barbieri, Angelo Paolo Dei Tos, Valentina Guarneri, Maria Vittoria Dieci, Matteo Fass |
| mTOR pathway candidate genes and energy intake interaction on breast cancer risk in Black women from the Women's Circle of Health Study. European journal of nutrition 2023 5 . Mmadili N Ilozumba, Lusine Yaghjyan, Susmita Datta, Jinying Zhao, Chi-Chen Hong, Kathryn L Lunetta, Gary Zirpoli, Elisa V Bandera, Julie R Palmer, Song Yao, Christine B Ambrosone, Ting-Yuan David Che |
| mTOR pathway candidate genes and physical activity interaction on breast cancer risk in black women from the women's circle of health study. Breast cancer research and treatment 2023 3 . Ilozumba Mmadili N, Yaghjyan Lusine, Datta Susmita, Zhao Jinying, Gong Zhihong, Hong Chi-Chen, Lunetta Kathryn L, Zirpoli Gary, Bandera Elisa V, Palmer Julie R, Yao Song, Ambrosone Christine B, Cheng Ting-Yuan Dav |
| TERT Promoter Mutation c.-124C>T Commonly Occurs in Low-Grade Fibromatosis-like Metaplastic Breast Carcinoma. Archives of pathology & laboratory medicine 2023 3 . Webersinke Gerald, Burghofer Jonathan, Malli Theodora, Rammer Melanie, Jahn Stephan Wenzel, Niendorf Axel, Tavassoli Fattaneh A, Moinfar Far |
| The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. European journal of medical research 2023 2 28 (1): 90. Cui Shengjin, Feng Jingying, Tang Xi, Lou Shuang, Guo Weiquan, Xiao Xiaowei, Li Shuping, Chen Xue, Huan Yu, Zhou Yiwen, Xiao Lij |
| Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies. Biomarker research 2023 2 11 (1): 21. Guan Xiuwen, Ma Fei, Li Qiao, Chen Shanshan, Lan Bo, Fan Ying, Wang Jiayu, Luo Yang, Cai Ruigang, Zhang Pin, Li Qing, Xu Bing |
| mTOR pathway candidate genes and obesity interaction on breast cancer risk in black women from the Women's Circle of Health Study. Cancer causes & control : CCC 2023 2 . Ilozumba Mmadili N, Yaghjyan Lusine, Datta Susmita, Zhao Jinying, Hong Chi-Chen, Lunetta Kathryn L, Zirpoli Gary, Bandera Elisa V, Palmer Julie R, Yao Song, Ambrosone Christine B, Cheng Ting-Yuan Dav |
| A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis. Breast disease 2024 6 43 (1): 213-221. Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargou |
| Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Cancer medicine 2024 6 13 (12): e7384. Shang-Hung Chen, Ka-Po Tse, Yen-Jung Lu, Shu-Jen Chen, Yu-Feng Tian, Kien Thiam Tan, Chien-Feng |
| p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 2024 1 . Hélène Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul H Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachel |
- Page last reviewed:Feb 1, 2024
- Content source: